Literature DB >> 11850124

Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells.

Antonietta Picascia1, Rosita Stanzione, Paolo Chieffi, Annamaria Kisslinger, Ivan Dikic, Donatella Tramontano.   

Abstract

Proline-rich tyrosine kinase 2 (Pyk2) expression in prostate epithelium inversely correlated with degree of malignancy of prostate cancers, thus the role of Pyk2 in the regulation of prostate cells proliferation and differentiation was investigate in PC3 cells. Pyk2 can be activated by canonic stimuli such as tumor necrosis factoralpha and lysophosphatidic acid (LPA) in PC3 cells, in addition, LPA stimulated Pyk2 phosphorylation also induced extracellular signal-regulated kinase 1 and 2 activation in these cells. Proliferation of PC3 cell clones (PC3-PKM) expressing a dominant negative kinase-defective Pyk2 mutant is consistently decreased in respect to that of wild type PC3 cells. In addition, PC3-PKM clones underwent total block cell proliferation upon treatment with dibutyryl cAMP. Finally, in the presence of sustained levels of intracellular cAMP, PC3-PKM cells, but not wild type PC3 cells, acquired a neuron-like morphology. Taken together our results suggest that Pyk2 plays a role in the regulation of prostate cell proliferation and, more interestingly, its expression may represents a sensitive marker of prostate state of differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850124     DOI: 10.1016/s0303-7207(01)00667-0

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  14 in total

Review 1.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.

Authors:  Terry W Moody; Alessia Di Florio; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2012-05-12       Impact factor: 3.444

3.  An up-date on epigenetic and molecular markers in testicular germ cell tumors.

Authors:  Paolo Chieffi
Journal:  Intractable Rare Dis Res       Date:  2017-11

4.  TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells.

Authors:  Siyang Zhang; Dawei Guo; Wenting Luo; Qingfu Zhang; Ying Zhang; Chunyan Li; Yao Lu; Zeshi Cui; Xueshan Qiu
Journal:  BMC Cancer       Date:  2010-02-16       Impact factor: 4.430

5.  Cardiac fibroblasts require focal adhesion kinase for normal proliferation and migration.

Authors:  Ana Maria Manso; Seok-Min Kang; Sergey V Plotnikov; Ingo Thievessen; Jaewon Oh; Hilary E Beggs; Robert S Ross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-09       Impact factor: 4.733

6.  Aurora B: A new promising therapeutic target in cancer.

Authors:  Paolo Chieffi
Journal:  Intractable Rare Dis Res       Date:  2018-05

7.  HCMV pUS28 initiates pro-migratory signaling via activation of Pyk2 kinase.

Authors:  Jennifer Vomaske; Susan Varnum; Ryan Melnychuk; Patricia Smith; Ljiljana Pasa-Tolic; Janani I Shutthanandan; Daniel N Streblow
Journal:  Herpesviridae       Date:  2010-12-07

8.  Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth.

Authors:  Xing Zhang; Li-hua Xu; Qiang Yu
Journal:  Mol Cancer       Date:  2010-01-14       Impact factor: 27.401

9.  Epac inhibits migration and proliferation of human prostate carcinoma cells.

Authors:  M Grandoch; A Rose; M ter Braak; V Jendrossek; H Rübben; J W Fischer; M Schmidt; A A Weber
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival.

Authors:  B-H Kuang; M-Q Zhang; L-H Xu; L-J Hu; H-B Wang; W-F Zhao; Y Du; X Zhang
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.